Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer
Status
Conditions
Treatments
Details and patient eligibility
About
The 18F-FDG-PET scan is currently being used for cancer diagnosis, staging, identifying hidden metastasis, and assessment of treatment responses in clinical oncology. Although there are important studies suggesting potential associations between PET-based parameters and oncologic outcomes, the calculation and official documentation of individual PET-based parameters might not be routine in clinical practice because these processes usually require time- and labor-consuming processes for the radiologists. In this study, the investigators prospectively determined clinical 18F-FDG-PET type according to degree of FDG-uptake in pancreatic cancer and compare oncologic outcomes between the types.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Candidate for radical pancreatectomy due to pancreatic cancer without neoadjuvant treatment
- Age between 20 years old and 80 years old
- General performance status greater than 70
- Results of peroperative PET-CT available
Exclusion criteria
- Unresectable, locally advance and metastatic pancreatic cancer
- Patients not wanting operation
- ASA score of greater than 3
- History of chronic alcoholism ot drug abuse
- Lack of patient compliance
- Patients not agreeing to enroll in the study.
- Patients unable to understand and sign the study agreement.
- History of neoadjuvant treatment
Trial design
200 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal